# To Evaluate the Safety and Efficacy of Sofosbuvir and Ribavirin in Patients With HCV (Genotype 3) Related Decompensated Cirrhosis

> **NCT02464631** · NA · TERMINATED · sponsor: **Institute of Liver and Biliary Sciences, India** · enrollment: 62 (actual)

## Conditions studied

- HCV Related Cirrhosis

## Interventions

- **DRUG:** Sofosbuvir + Ribavirin 1
- **DRUG:** Sofosbuvir + Ribavirin 2
- **DRUG:** Sofosbuvir + Ribavirin 3

## Key facts

- **NCT ID:** NCT02464631
- **Lead sponsor:** Institute of Liver and Biliary Sciences, India
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-06
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 62 (ACTUAL)
- **Why stopped:** In view of recent approval of NS5A inhibitors for treatment of hepatitis C such as Declatasvir and Ledipasvir which have proven better efficacy in the HCV cure
- **Last updated:** 2017-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02464631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02464631, "To Evaluate the Safety and Efficacy of Sofosbuvir and Ribavirin in Patients With HCV (Genotype 3) Related Decompensated Cirrhosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02464631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*